to all studies involving investigational products under INDs or IDEs.

Evolution Toward Centralized Oversight

Historically, IRBs were local committees at academic centers. Over time, multi-site trials revealed inefficiencies in duplicative reviews, leading to NIH’s 2016 Single IRB (sIRB) policy for federally funded multi-site studies and FDA’s 2020 guidance on cooperative IRB review arrangements. Central IRBs and commercial IRBs now play major roles, especially in industry-sponsored, multi-center studies. Reliance agreements formalize responsibilities when one IRB serves as the IRB of record.

Case Example—Single IRB in Oncology Network

A multi-institution oncology trial adopted a single IRB model. By using reliance agreements and standardized consent templates, the trial reduced start-up time by nearly three months, while still allowing local context review through community representatives.

Core Clinical Trial Insights

1) IRB Composition and Membership

Regulations require at least five members, with diversity in background, gender, and expertise, including at least one scientific member, one nonscientific member, and one unaffiliated member. Institutions often add community representatives and legal experts. Conflict of interest policies prevent members with study-related interests from voting. Membership rosters and training records are subject to FDA BIMO inspection.

2) IRB Responsibilities in Protocol Review

IRBs evaluate risk–benefit ratios, inclusion/exclusion criteria, informed consent documents, recruitment materials, compensation, and privacy protections. They must ensure that risks are minimized and reasonable relative to anticipated benefits. Protocols must provide sufficient monitoring, safety reporting, and stopping rules. IRBs document their decisions in written communications to investigators and maintain detailed minutes.

3) Informed Consent Oversight

IRBs review and approve informed consent forms (ICFs) to ensure compliance with 21 CFR 50 requirements: understandable language, disclosure of risks, benefits, alternatives, confidentiality, and voluntary participation. The revised Common Rule requires a concise “Key Information” summary at the start of consent forms. IRBs also oversee ongoing consent processes and require re-consent after major protocol amendments or new safety information.

4) Continuing Review and Monitoring

IRBs must conduct continuing review of approved protocols at least annually, unless exempt under the revised Common Rule for minimal risk studies. Reviews cover enrollment status, AE/SAE reports, protocol deviations, and interim findings. IRBs also review changes in study staff or sites. Failure to obtain timely continuing review approval can halt a study.

5) Expedited vs. Full Board Review

Minimal-risk research or minor changes may qualify for expedited review by the IRB chair or designated reviewers. Studies involving greater than minimal risk, vulnerable populations, or investigational drugs typically require full board review with quorum. IRB determinations must be documented and communicated promptly to investigators.

6) IRB–FDA Interactions

FDA inspects IRBs under the Bioresearch Monitoring Program (BIMO). Common findings include inadequate membership rosters, incomplete meeting minutes, and failure to follow written procedures. FDA can issue Warning Letters to IRBs for systemic non-compliance. IRBs must cooperate with FDA inspections and provide records upon request.

7) Reliance Agreements and Cooperative Review

When multiple institutions participate, reliance agreements specify which IRB has oversight and how responsibilities are shared. The NIH policy mandates single IRB review for multi-site federally funded studies, with reliance agreements coordinated via the SMART IRB platform. Commercial IRBs often serve as IRBs of record in industry-sponsored trials.

8) Vulnerable Populations

IRBs apply additional safeguards for children, pregnant women, prisoners, and cognitively impaired individuals. They assess risk/benefit justifications, consent/assent processes, and monitoring plans. Specialized expertise may be co-opted into meetings when such populations are involved.

9) Recruitment and Advertising Oversight

All recruitment materials—flyers, social media posts, scripts—must be reviewed and approved by the IRB to prevent undue influence or misleading claims. Payment to participants must be fair and not coercive, and schedules must be transparent in the ICF.

10) Recordkeeping and Documentation

IRBs must maintain detailed records: membership rosters, written procedures, protocol files, correspondence, minutes, consent forms, and continuing review reports. Retention is typically three years after study completion or longer if institutional policy requires.

Best Practices & Preventive Measures

Sponsors and investigators should build IRB collaboration into trial planning: use standardized consent templates, budget realistic timelines for review cycles, align recruitment materials early, and establish strong communication with IRB coordinators. For multi-site trials, reliance agreements should be drafted early. IRBs should invest in training, adopt electronic systems, and periodically audit their procedures to ensure readiness for FDA inspection.

Scientific & Regulatory Evidence

Key references include 21 CFR 50 and 56, the Common Rule (45 CFR 46), FDA’s Information Sheets Guidance for IRBs, OHRP guidance on informed consent, and ICH E6(R2) GCP. These documents collectively define IRB authority, investigator obligations, and ethical requirements. FDA’s 2019 guidance on cooperative research clarifies the use of single IRBs, and OHRP maintains an online IRB registration database.

Special Considerations

Digital health and decentralized trial designs are expanding IRB responsibilities. Boards must assess telemedicine consent, e-signatures, and digital recruitment. IRBs also face increasing scrutiny regarding diversity and inclusion—ensuring that recruitment strategies equitably include underrepresented populations. Academic IRBs may differ in speed and resources compared to commercial IRBs; sponsors should evaluate trade-offs when selecting oversight models.

When Sponsors Should Seek Regulatory Advice

Sponsors may request FDA input on IRB-related concerns, especially when developing novel consent processes, digital platforms, or protocols involving high-risk populations. Engaging OHRP or FDA early helps clarify requirements and avoid delays. Sponsors should also consult IRBs during protocol development, not just at submission, to identify ethical concerns proactively.

Case Studies

Case Study 1: IRB Warning Letter for Inadequate Minutes

An IRB received a Warning Letter after FDA found that meeting minutes failed to document risk–benefit discussions and votes. Corrective actions included standardized templates, dedicated notetakers, and periodic audits.

Case Study 2: Central IRB Success in Rare Disease Trial

A biotech sponsor used a central IRB for a 15-site rare disease study. Reliance agreements reduced delays and harmonized consent documents. Enrollment began six weeks earlier than in similar prior studies using local IRBs.

Case Study 3: Digital Consent Pilot

An IRB approved an eConsent system for a decentralized dermatology trial. Audit trails, multimedia modules, and comprehension quizzes ensured regulatory compliance while enhancing patient understanding.

FAQs

1) What is the difference between FDA and OHRP authority over IRBs?

FDA regulates IRBs for studies involving drugs, biologics, and devices under INDs/IDEs; OHRP oversees federally funded research. Many institutions fall under both.

2) Do all U.S. clinical trials require IRB approval?

Yes, any study involving human subjects under FDA jurisdiction or federal funding must receive IRB approval before initiation.

3) How quickly can an IRB review a new study?

Expedited reviews may be completed within 1–2 weeks; full board reviews typically require 3–6 weeks depending on schedules and completeness.

4) Can sponsors select commercial IRBs instead of institutional ones?

Yes, commercial IRBs are widely used in industry-sponsored multi-site trials for efficiency, though some institutions mandate local IRB involvement.

5) How do IRBs handle conflicts of interest?

Members with study-related financial or professional conflicts must recuse themselves from voting; COI policies are mandatory and subject to FDA inspection.

6) Are recruitment ads subject to IRB review?

Yes, all advertising materials intended for participant recruitment must be IRB-approved to prevent undue influence or false claims.

7) What are common IRB deficiencies found during FDA inspections?

Inadequate rosters, incomplete minutes, failure to follow written procedures, delayed reviews, and insufficient documentation of risk–benefit assessments.

8) How do IRBs ensure compliance in decentralized trials?

By reviewing eConsent platforms, verifying telemedicine compliance, and ensuring that privacy protections meet regulatory standards.

9) Are continuing reviews always required?

Yes for FDA-regulated studies. Under the revised Common Rule, some minimal-risk federally funded studies may be exempt, but FDA still requires continuing review.

10) Can an IRB be disqualified?

Yes, FDA can disqualify an IRB for systemic non-compliance, though this is rare. Sponsors must then seek alternative IRB review for affected studies.

Conclusion & Call-to-Action

IRBs remain the cornerstone of ethical oversight in U.S. clinical trials. Sponsors and investigators who understand IRB composition, processes, and expectations can accelerate approvals while maintaining compliance. Proactive collaboration with IRBs—through standardized templates, reliance agreements, and early ethical input—ensures that trials begin on time, protect participants, and stand up to FDA scrutiny. As digital and decentralized methods expand, IRBs will continue to evolve as critical partners in safeguarding human research.